Expect near-term stock weakness from dilution and increased leverage. The convertible note arbitrage may drive short interest. Key catalyst is the June 30 PDUFA for veligrotug; positive outcome could offset dilution concerns. Monitor the concurrent equity offering closing and any updates on elegrobart BLA timing.
Price Chart
Executive Summary
Viridian Therapeutics is raising $225M via 1.75% convertible notes due 2032 (plus $25M over-allotment) and concurrently offering $125M of common stock. Proceeds will repay $50.4M secured debt, fund TED franchise expansion, and advance the pipeline. The combined $350M gross raise causes significant dilution (~7% from equity alone), though it extends the cash runway past the critical PDUFA date for veligrotug on June 30, 2026.
Key Facts
- $225M aggregate principal of 1.75% convertible senior notes due 2032 (up to $250M with over-allotment)
- Concurrent equity offering of 7,352,942 shares (or up to 8,455,883) at $17.00 per share
- Initial conversion price approximately $24.65 per share, ~40% above current stock price $17.53
- Use of proceeds: repay $50.4M Hercules secured debt, fund market expansion studies for TED franchise, advance earlier pipeline
- Net proceeds ~$217.7M from notes and ~$117M from equity offering (assuming no over-allotment)
- Recent positive REVEAL-2 Phase 3 data for elegrobart (subcutaneous IGF-1R inhibitor for TED) met primary and key secondary endpoints
- PDUFA date for veligrotug (IV anti-IGF-1R) is June 30, 2026
Financial Impact
Combined gross proceeds of $350M ($225M notes + $125M equity) represent ~19% of pre-offering market cap ($1.8B). Equity offering dilutes existing shareholders by ~7.2% based on 102.5M shares outstanding. Convertible notes add $225M debt with potential further dilution if converted.
Risk Factors
- Dilution from equity offering and potential conversion of notes
- Increased leverage with $225M additional debt
- Execution risk on TED franchise commercialization and pipeline advancement
- Stock price below conversion price may limit note conversion and create overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-214614 |
| Document: d125234dexfilingfees.htm | 0001193125-26-214614 |
| Document: 0001193125-26-214614-index-headers.html | 0001193125-26-214614 |
| Document: 0001193125-26-214614-index.html | 0001193125-26-214614 |
| Document: 0001193125-26-214614.txt | 0001193125-26-214614 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $22.51 $22.96 | ▲ +2.00% | ▲ +1.40% | $24.09 (+7.02%) |
May 28, 2026 21w ago | 8-K | $17.62 $18.79 | ▲ +6.64% | ▲ +8.43% | $24.09 (+36.72%) |
May 26, 2026 22w ago | 8-K | $17.26 $17.39 | ▲ +0.75% | ▲ +2.65% | $24.09 (+39.57%) |
May 8, 2026 24w ago | 424B5 | $17.20 $16.31 | ▲ +5.17% | ▲ +4.87% | $24.09 (−40.06%) |
May 5, 2026 24w ago | 424B5 | $17.53 $16.35 | ▼ −6.73% | ▼ −9.51% | $24.09 (+37.42%) |
May 5, 2026 25w ago | 8-K | $18.75 $15.87 | ▼ −15.36% | ▼ −20.31% | $24.09 (+28.48%) |
Apr 17, 2026 27w ago | DEFA14A | $14.80 $17.43 | ▲ +17.77% | ▲ +12.40% | $24.09 (+62.77%) |
Feb 26, 2026 34w ago | 8-K | $29.49 $28.20 | ▼ −4.37% | ▲ +2.03% | $24.09 (−18.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers